Vistagen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday

Vistagen Therapeutics (NASDAQ:VTGN) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.30 million. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative return on equity of 35.12%. During the same quarter in the previous year, the company earned ($0.94) earnings per share. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vistagen Therapeutics Stock Up 1.0 %

VTGN stock opened at $3.11 on Friday. Vistagen Therapeutics has a 52 week low of $2.45 and a 52 week high of $5.86. The firm has a 50-day simple moving average of $3.13 and a 200-day simple moving average of $3.62. The stock has a market capitalization of $84.16 million, a P/E ratio of -2.10 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Separately, William Blair raised shares of Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.